Seltamet Tablet 50/1000 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
MFDS item code 202200321 · Approved 2022.01.19
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to help manage blood glucose levels in patients with type 2 diabetes. It may be administered to individuals who find it difficult to control their blood sugar levels with monotherapy when starting diabetes medications. Additionally, it serves as an alternative when monotherapy with either metformin or sitagliptin is insufficient, or when both medications are used together. It is also utilized in conjunction with metformin if blood glucose control is still inadequate when used with sulfonylureas or with thiazolidinediones. Insulin can also be supplemented with this medication if blood sugar levels are not adequately controlled. In summary, this medication is used to support blood glucose control in various situations where existing treatments are ineffective.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medication is determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this medication 50/500 mg twice daily. The dose may be increased to 1 tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Do not administer to the following patients). 2. Patients receiving metformin: - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg), and the initial dose of metformin should take the patient's blood glucose level and current dose into consideration. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Studies evaluating the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medication have not been conducted. Since any change in treatment for type 2 diabetes mellitus may affect glycemic control, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Do not administer to the following patients).
This medication contains sitagliptin and metformin, which are used for diabetes treatment. First, serious allergic reactions may occur while taking this medication; if symptoms such as rash, hives, difficulty breathing, or swelling of the face or neck arise, discontinue use immediately and consult a physician. Additionally, this medication may cause pancreatitis, so if symptoms such as abdominal pain, vomiting, or nausea appear, it is important to visit a hospital promptly. Due to the metformin component, lactic acidosis—a rare yet fatal metabolic disturbance—may occur; therefore, one should be cautious of symptoms such as shortness of breath, muscle pain, fatigue, abdominal pain, and confusion. Patients with poor kidney function, severe infections, dehydration, acute heart problems, or heart failure should not take this medication. Temporary discontinuation of this medication is required before and after tests using iodinated contrast agents, and it can be resumed after kidney function is confirmed to be normal. It is safer for women who are pregnant, potentially pregnant, or breastfeeding not to take this medication. During treatment, irregular meals, excessive exercise, and interactions with other medications can increase the risk of hypoglycemia or lactic acidosis. This medication may cause side effects such as diarrhea, nausea, vomiting, abdominal pain, headache, upper respiratory infection, etc., and especially when taken with other hypoglycemic agents, symptoms of hypoglycemia may occur. Regular blood tests and kidney function assessments are necessary, and checking vitamin B12 levels is also recommended. Alcohol consumption can increase the risk of lactic acidosis; therefore, excessive drinking should be avoided during treatment. If a surgery is planned or in cases of severe infection or severe trauma, temporary discontinuation of this medication is warranted. Care should be taken during activities such as driving or operating dangerous machinery while using this medication, especially regarding symptoms of hypoglycemia or lactic acidosis. In case of overdose, seek immediate medical attention for appropriate treatment, and if necessary, the drug can be removed via dialysis.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture. Ideal storage temperature is between 1 and 30 degrees Celsius at room temperature. Proper storage will help maintain the effectiveness of the medication for a longer period.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Celltrion Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.